1-9 of 9
urate oxidase
Close
Sort by
Journal Articles

A Phase II Non-Randomized Study to Evaluate the Efficacy of Single Dose Rasburicase (1.5mg) in Adult Acute Leukemia and High Grade Lymphomas with Established Tumor Lysis Syndrome

Jayshree Thorat, MD, Swaratika Majumdar, MDDM, Hasmukh Jain, MD DM, Avinash Bonda, MD DM, Lingaraj Nayak, MDDM MDcal Oncology, Bhausaheb Bagal, MD DM, Manju Sengar, MD DM
Journal: Blood
Blood (2019) 134 (Supplement_1): 2914.
https://doi.org/10.1182/blood-2019-128755
Published: 2019
Journal Articles

A Comparison of Single Dose Rasburicase 3 Mg Versus 6 Mg for the Management of Tumor Lysis Syndrome

Sarah K Kraus, PharmD, Catherine E Burdalski, PharmD, Colleen Timlin, PharmD, BCOP, Tracy M Krause, PharmD, BCOP, Todd A Miano, PharmD, MSCE, Jakub Svoboda, MD, Alex Ganetsky, PharmD, BCOP
Journal: Blood
Blood (2015) 126 (23): 4511.
https://doi.org/10.1182/blood.V126.23.4511.4511
Published: 2015
Journal Articles

Serum Uric Acid Levels during Allogeneic Hematopoeitic Cell Transplantation and Subsequent Graft Versus Host Disease

Albert C Yeh, MD, Thomas R. Spitzer, MD, Yi-Bin Chen, MD, Steven McAfee, MD, Karen K. Ballen, MD, Eyal C. Attar, MD, Amir T. Fathi, MD, Bimalangshu R. Dey, MD PhD
Journal: Blood
Blood (2014) 124 (21): 2493.
https://doi.org/10.1182/blood.V124.21.2493.2493
Published: 2014
Journal Articles

Urate Oxidase (Rasburicase) to Inhibit Graft Versus Host Disease (GVHD) After Myeloablative HLA-Matched Allogeneic Hematopoietic Cell Transplantation (HCT).

Andrew M. Brunner, MD, Thomas R. Spitzer, MD, Yi-Bin A. Chen, MD, Erin Coughlin, Steven L. McAfee, MD, Karen K. Ballen, MD, Eyal C. Attar, MD, Martin Caron, Frederic I. Preffer, PhD, Beow Y Yeap, ScD, Bimalangshu R Dey, MD
Journal: Blood
Blood (2012) 120 (21): 3063.
https://doi.org/10.1182/blood.V120.21.3063.3063
Published: 2012
Journal Articles

Concomitant Usage of Rasburicase and Allopurinol May Augment Toxic Epidermal Necrolysis Syndrome TEN

Ahmad Jajeh, MD, MPH
Journal: Blood
Blood (2010) 116 (21): 4949.
https://doi.org/10.1182/blood.V116.21.4949.4949
Published: 2010
Journal Articles

Pharmacokinetics of Intravenous Uricase-PEG 20, a Drug for Managing Hyperuricemia in Tumor Lysis Syndrome.

Zhihua Zhang, MD, PhD, Anthony Fiorino, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 3086.
https://doi.org/10.1182/blood.V114.22.3086.3086
Published: 2009
Journal Articles

Low-Dose Recombinante Urate Oxidase (Rasburicase) Is Effective in Treating Hyperuricemia in Patients with Hematologic Malignancies.

S. Trifilio, A. Evens, L. Gordon, S. Singhal, M. Tallman, J. Mehta
Journal: Blood
Blood (2005) 106 (11): 3123.
https://doi.org/10.1182/blood.V106.11.3123.3123
Published: 2005
Journal Articles

Low-Dose Recombinante Urate Oxidase (Rasburicase) Is Effective in Hyperuricemia.

S. Trifilio, M. Tallman, S. Singhal, L. Gordon, A. Evens, J. Mehta
Journal: Blood
Blood (2004) 104 (11): 3312.
https://doi.org/10.1182/blood.V104.11.3312.3312
Published: 2004
Journal Articles

A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis: Presented in part at the American Society of Hematology Conference in Miami Beach, FL, December 1998.

Clinical Trials & Observations
Stanton C. Goldman, John S. Holcenberg, Jerry Z. Finklestein, Raymond Hutchinson, Susan Kreissman, F. Leonard Johnson, Conrad Tou, Elizabeth Harvey, Erin Morris, Mitchell S. Cairo
Journal: Blood
Blood (2001) 97 (10): 2998–3003.
https://doi.org/10.1182/blood.V97.10.2998
Published: 2001